Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: Proposing a wait time "sweet Spot"

Transplantation

Volumn 101, Issue 9, 2017, Pages 2071-2078

  Mehta, Neil ^a   Heimbach, Julie ^b   Lee, David ^c   Dodge, Jennifer L ^a   Harnois, Denise ^c   Burns, Justin ^c   Sanchez, William ^b   Roberts, John P ^a   Yao, Francis Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CHEMOEMBOLIZATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; END STAGE LIVER DISEASE; ETHNICITY; FEMALE; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROBABILITY; ADVERSE EFFECTS; AGED; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT DROPOUT; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TIME TO TREATMENT; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PATIENT DROPOUTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME; UNITED STATES; WAITING LISTS;

EID: 85016403112     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001752     Document Type: Article

References (38)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
2. Massie AB, Caffo B, Gentry SE, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant. 2011;11:2362-2371.
3. Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report. Lancet Oncol. 2012;13:e11-e22.
4. Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl. 2010;16:262-278.
5. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: Impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134:1342-1351.
6. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7:2587-2596.
7. Sharma P,Welch K, Hussain H, et al. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci. 2012;57:806-812.
8. ZimmermanMA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: A review of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143:182-188.
9. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
10. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509.
11. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: A model including-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986-994.
12. Hameed B,Mehta N, Sapisochin G, et al. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20: 945-951.
13. Hakeem AR, Young RS, Marangoni G, et al. Systematic review: The prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987-999.
14. Gouw AS, Balabaud C, Kusano H, et al. Markers for microvascular invasion in hepatocellular carcinoma: Where do we stand Liver Transpl. 2011;17(Suppl 2):S72-S80.
15. Mehta N, Yao FY. Moving past "one size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013;19:1055-1058.
16. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127(Suppl 1):S277-S282.
17. Roberts JP, Venook A, Kerlan R, et al. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010;16:925-929.
18. Halazun KJ, Patzer RE, Rana AA, et al. Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014; 60:1957-1962.
19. Schlansky B, Chen Y, Scott DL, et al. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: A cohort study using the United Network for Organ Sharing registry. Liver Transpl. 2014;20: 1045-1056.
20. Samoylova ML, Dodge JL, Yao FY, et al. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2014;20:937-944.
21. Mehta N, Dodge JL, Goel A, et al. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: Implications for the current organ allocation policy. Liver Transpl. 2013;19:1343-1353.
22. Heimbach JK, Hirose R, Stock PG, et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology. 2015;61:1643-1650.
23. Organ Procurement and Transplantation Network. Policies. Available at: Https://optn.transplant.hrsa.gov/media/1200/optn-policies.pdf. Updated March 1, 2017. Accessed October 21, 2016.
24. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
25. Fine JP, Gray RJ. A proportional hazardsmodel for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
26. Washburn K, Edwards E, Harper A, et al. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant. 2010;10:1643-1648.
27. Terzi E, Piscaglia F, Forlani L, et al. TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer. 2014;14:601.
28. Volk ML. Unfair priority for HCC: A problem whose ideal solution remains unsolved. Am J Transplant. 2010;10:1507-1508.
29. Goldberg D, French B, Abt P, et al. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl. 2012;18:434-443.
30. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl. 2003;9:684-692.
31. Chauhan R, Lahiri N. Tissue-A nd serum-associated biomarkers of hepatocellular carcinoma. Biomark Cancer. 2016;8(Suppl 1):37-55.
32. Chaiteerakij R, Zhang X, Addissie BD, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015;21:599-606.
33. von Felden J, Heim D, Schulze K, et al. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer. 2017;17:60.
34. Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19:1108-1118.
35. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12:1260-1267.
36. Kim DJ, Clark PJ, Heimbach J, et al. Recurrence of hepatocellular carcinoma: Importance of mRECIST response to chemoembolization and tumor size. Am J Transplant. 2014;14:1383-1390.
37. Terzi E, Kim WR, Sanchez W, et al. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015;21:248-257.
38. Salvalaggio PR, Felga G, Axelrod DA, et al. List and liver transplant survival according to waiting time in patients with hepatocellular carcinoma. Am J Transplant. 2015;15:668-677.